Home/Filings/4/0001209191-21-012361
4//SEC Filing

Verstandig Grant 4

Accession 0001209191-21-012361

CIK 0001538210other

Filed

Feb 18, 7:00 PM ET

Accepted

Feb 19, 4:25 PM ET

Size

9.1 KB

Accession

0001209191-21-012361

Insider Transaction Report

Form 4
Period: 2021-02-17
Transactions
  • Conversion

    Common Stock

    2021-02-17+539,895539,895 total
  • Purchase

    Common Stock

    2021-02-17$17.00/sh+175,000$2,975,000714,895 total
  • Conversion

    Convertible Promissory Note

    2021-02-170 total
    Common Stock (539,895 underlying)
Footnotes (3)
  • [F1]On February 17, 2021 (the "Closing"), the convertible promissory notes (the "Notes") became automatically convertible into shares of the Issuer's common stock. At the Closing, the principal amount of the Notes, plus accrued but unpaid interest thereon through February 17, 2021, converted into shares of the Issuer's common stock by dividing the principal and accrued but unpaid interest under such Note by the price per share obtained by dividing $125,000,000 by the Company's fully-diluted capitalization immediately prior to the IPO, assuming exercise or conversion of all convertible securities of the Company but excluding any shares issuable upon conversion of the Notes.
  • [F2]Reflects shares purchased in the Issuer's initial public offering.
  • [F3]Not applicable.

Issuer

NexImmune, Inc.

CIK 0001538210

Entity typeother

Related Parties

1
  • filerCIK 0001843817

Filing Metadata

Form type
4
Filed
Feb 18, 7:00 PM ET
Accepted
Feb 19, 4:25 PM ET
Size
9.1 KB